9
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T12456 | PI3K-IN-10 | PI3K | |
PI3K-IN-10 is a potent inhibitor of pan-PI3K . | |||
T64219 | PI3K/mTOR Inhibitor-6 | ||
PI3K/mTOR Inhibitor-6 (Compound 19c) is a potent dual PI3K/mTOR inhibitor that is more stable than gedatolisib in artificial gastric fluid. 10 μM of PI3K/mTOR Inhibitor-6 significantly inhibits the PI3K/Akt/mTOR signalli... | |||
T62409 | PI3K-IN-23 | ||
PI3K-IN-23 is a (E)-9-oxooctadec-10-en-12-ynoic acid analogue that promotes glucose uptake (EC50: 7.00 μM). | |||
T64041 | PI3K/mTOR Inhibitor-7 | ||
PI3K/mTOR Inhibitor-7 is a potent dual PI3K/mTOR inhibitor. PI3K/mTOR Inhibitor-7 is 4.7-fold more potent than gedatolisib, with IC50 values of 1.4 μM and 0.3 μM, respectively. 10 μM of PI3K/mTOR Inhibitor-7 is able to s... | |||
T63211 | AKT-IN-10 | ||
AKT-IN-10 is a potent AKT inhibitor that has shown research potential in breast and prostate cancers. Among them is protein kinase B (PKB, also known as AKT), which is central to PI3K/AKT/mTOR signaling in cells and whos... | |||
T79449 | Antileishmanial agent-19 | Parasite | |
Compound F27 (Antileishmanial agent-19) is an antileishmanial compound effective against L. donovani promastigotes, demonstrating an IC50 of 3.39 μM. It functions by inhibiting the Leishmania prolyl-tRNA synthetase and d... | |||
T36421 | Immuno-Oncology Screening Library | ||
The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library include... | |||
T78871 | PLM-101 | ||
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET. It impedes RET function, promoting autophagic breakdown of FLT3, and suppresses the PI3K and Ras/ERK pathways, con... | |||
T36308 | PF-06843195 | ||
PF-06843195 is a selective PI3Kα inhibitor, demonstrating potent activity with an IC50 of 18 nM in Rat1 fibroblasts and Kis for PI3Kα and PI3Kδ less than 0.018 nM and 0.28 nM, respectively, in biochemical kinase assays. ... |